

SUPPLEMENTAL MATERIAL

Figure I: PRIMSA diagram referenced in Feldman et al.¹




Table I: Disaggregated data from trials in review

Trial	Date	Region	Intervention	# Participants	# Sites	Trial duration (mo)	Maximum time to intervention (hrs)	t-PA given	Recruitment rate (indiv/mo)	Recruitment efficiency (indiv/site/mo)
Early Stroke Trial Group ²	1994	North America	Monosialoganglioside GM-1	792	16	36	5	No	22.0	1.4
MAST-I Study Group ³	1995	Europe	streptokinase/aspirin	622	70	46	6	Yes	13.5	0.2
NINDS rt-PA Stroke Study Group ⁴	1995	North America	alteplase	624	36	46	3	Yes	13.6	0.4
ECASS Study Group ⁵	1995	Europe	alteplase	620	75	16	6	Yes	38.8	0.5
RANTTAS Investigators ⁶	1996	North America	tirilazad	660	27	20	6	No	33.0	1.2
MAST-E Study Group ⁷	1996	Europe	streptokinase	310	48	24	6	Yes	12.9	0.3
ASK Study Group ⁸	1996	Australia	streptokinase	340	40	31	4	Yes	11.0	0.3
PASS Group ⁹	1997	Europe	piracetam	927	55	39	12	No	23.8	0.4
ECASS II Investigators ¹⁰	1998	Multiple	alteplase	800	100	16	6	Yes	50.0	0.5
ATLANTIS Study Investigators ¹¹	1999	North America	alteplase	613	140	56	5	Yes	10.9	0.1
Cervene Stroke Study Investigators ¹²	2000	North America	nalmafene	368	45	21	6	Yes	17.5	0.4
GAIN International Investigators ¹³	2000	Multiple	gavestinel	1804	173	15	6	No	120.3	0.7
LUB-INT 13 Investigators ¹⁴	2000	Multiple	lubeluzole	1786	131	23	8	No	77.7	0.6
STAT Participants ¹⁵	2000	North America	ancrod	500	48	54	3	No	9.3	0.2
GAIN Americas Investigators ¹⁶	2001	North America	gavestinel	1646	132	19	6	Yes	86.6	0.7
Aptiganel Acute Stroke Investigators ¹⁷	2001	Multiple	aptiganel	628	156	15	6	No	41.9	0.3
Enlimomab Acute Stroke Trial Investigators ¹⁸	2001	North America	enlimomab	625	67	21	6	No	29.8	0.4
IMAGES Study Investigators ¹⁹	2004	Multiple	magnesium	2589	99	67	12	Yes	38.6	0.4
ALIAS Investigators ²⁰	2011	North America	albumin	434	62	18	5	Yes	24.1	0.4

CASTA Investigators ²¹	2012	Asia	cerebrolysin	1070	51	49	12	Yes	21.8	0.4
IST-3 Collaborative Group ²²	2012	Multiple	rt-PA	3035	156	135	6	Yes	22.5	0.1
ARTIS Investigators ²³	2012	Europe	aspirin	642	37	34	6	Yes	18.9	0.5
IMS III ²⁴	2013	Multiple	endovascular	656	58	69	3.7	Yes	9.5	0.2
MACSI ²⁵	2013	Multiple	DP-b99	446	154	26	9	No	17.2	0.1
SYNTHESIS Expansion Investigators ²⁶	2013	Europe	endovascular	362	24	51	4.5	Yes	7.1	0.3
AXIS 2 Investigators ²⁷	2013	Europe	G-CSF	328	78	24	9	Yes	14.0	0.2
ALIAS and NETT Investigators ²⁸	2013	Multiple	albumin	848	89	44	5	Yes	19.3	0.2
URICO-ICTUS Investigators ²⁹	2014	Europe	uric acid	421	10	22	4.5	No	19.1	1.9

References

1. Feldman WB, Kim AS, Josephson SA, Lowenstein DH, Chiong W. Effect of waivers of consent on recruitment in acute stroke trials: A systematic review. *Neurology*. 2016;86:1543-1551.
2. Lenzi GL, Grigoletto F, Gent M, Roberts RS, Walker MD, Easton DE, et al. Early treatment of stroke with monosialoganglioside GM-1: Efficacy and safety results of the Early Stroke Trial. *Stroke*. 1994;25:1552-1558.
3. Multicentre Acute Stroke Trial--Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. *Lancet*. 1995;346:1509-1514.
4. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med*. 1996;334:1405-1406.
5. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). *JAMA*. 1995;274:1017-1025.
6. The RANTTAS Study Group. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). *Stroke*. 1996;27:1453-1458.
7. The Multicenter Acute Stroke Trial - Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. *N Engl J Med*. 1996;335:145-150.
8. Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, et al. Streptokinase for acute ischemic stroke with relationship to time of administration. *JAMA*. 1996;276:961-966.
9. De Deyn PP, De Reuck J, Deberdt W, Vlietinck R, Orgogozo J-M, for members of the Piracetam in Acute Stroke (PASS) Group. Treatment of Acute Ischemic Stroke With Piracetam. *Stroke*. 1997;28:2347-2352.
10. Hacke W, Kaste M, Fieschi C, Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). *Lancet*. 1998;352:1245-1251.
11. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: The ATLANTIS Study: a randomized controlled trial. *JAMA*. 1999;282:2019-2026.
12. Clark WM, Raps EC, Tong DC, Kelly RE, for the Cervene Stroke Study Investigators. Cervene (nalmefene) in acute ischemic stroke: final results of a phase III efficacy study. *Stroke*. 2000;31:1234-1239.
13. Lees KR, Asplund K, Carolei A, Davis SM, Diener H-C, Kaste M, et al. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. *Lancet*. 2000;355:1949-1954.
14. Diener HC, Cortens M, Ford G, Grotta J, Hacke W, Kaste H, et al. Lubeluzole in acute ischemic stroke treatment: A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. *Stroke*. 2000;31:2543-2551.
15. Sherman DG, Atkinson RP, Chippendale T, Levin KA, Ng K, Futrell N, et al. Intravenous ancrod for treatment of acute ischemic stroke: The STAT study: A randomized controlled trial. *JAMA*. 2000;283:2395-2403.
16. Sacco RL, DeRosa JT, Haley EC, Levin B, Ordroneau P, Phillips SJ, et al. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. *JAMA*. 2001;285:1719-1728.
17. Albers GW, Goldstein LB, Hall D, Lesko LM, for the Aptiganel Acute Stroke Investigators. Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. *JAMA*. 2001;286:2673-2682.
18. Enlimomab Acute Stroke Trial Investigators. Use of anti-ICAM-1 therapy in ischemic stroke: Results of the Enlimomab Acute Stroke Trial. *Neurology*. 2001;57:1428-1434.
19. Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): Randomised controlled trial. *Lancet*. 2004;363:439-445.
20. Ginsberg MD, Palesch YY, Martin RH, Hill MD, Moy CS, Waldman BD, et al. The albumin in acute stroke (ALIAS) multicenter clinical trial: Safety analysis of part 1 and rationale and design of part 2. *Stroke*. 2011;42:119-127.
21. Heiss W-D, Brainin M, Bornstein NM, Tuomilehto J, Hong Z, for the Cerebrolysin in Acute Stroke Treatment (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: Results of a double-blind, placebo-controlled randomized trial. *Stroke*. 2012;43:630-636.
22. The IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. *Lancet*. 2012;379:2352-2363.
23. Zinkstok SM, Roos YB, on behalf of the ARTIS investigators. Early administration of aspirin in patients treated

- with alteplase for acute ischaemic stroke: a randomised controlled trial. *Lancet*. 2012;380:731-737.
24. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. *N Engl J Med*. 2013;368:893-903.
 25. Lees KR, Bornstein N, Diener H-C, Gorelick PB, Rosenberg G, Shuaib A, et al. Results of Membrane-Activated Chelator Stroke Intervention randomized trial of DP-b99 in acute ischemic stroke. *Stroke*. 2013;44:580-584.
 26. Ciccone A, Valvassori L, Nichelatti M, Sgoifo A, Ponzio M, Sterzi R, et al. Endovascular treatment for acute ischemic stroke. *N Engl J Med*. 2013;368:904-913.
 27. Ringelstein EB, Thijs V, Norrving B, Chamorro A, Aichner F, Grond M, et al. Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. *Stroke*. 2013;44:2681-2687.
 28. Ginsberg MD, Palesch YY, Hill MD, Martin RH, Moy CS, Barsan WG, et al. High-dose albumin treatment for acute ischaemic stroke (ALIAS) part 2: A randomised, double-blind, phase 3, placebo-controlled trial. *Lancet Neurol*. 2013;12:1049-1058.
 29. Chamorro A, Amaro S, Castellanos M, Segura T, Arenillas J, Martí-Fàbregas J, et al. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. *Lancet Neurol*. 2014;13:453-460.